New triple therapy aims to beat drug-resistant cancers
NCT ID NCT05383482
First seen Nov 17, 2025 · Last updated May 13, 2026 · Updated 20 times
Summary
This study tested a combination of three drugs (afuresertib, sintilimab, and chemotherapy) in 22 adults with solid tumors like lung, cervical, or stomach cancer that had stopped responding to prior immunotherapy. The goal was to find the safest dose and see if the combo could shrink tumors. The study is complete, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Chongqing Cancer Hospital
Chongqing, Chengdu, China
-
Jilin Cancer Hospital
Changchun, Jilin, China
-
West China Second University Hosital, Sichuan University
Chengdu, Sichuan, China
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.